While mechanisms that target actin cytoskeleton genes are proposed forms of cancer therapeutics in other studies [44,45] our findings indicate precision strategies against ACTG1 could yield benefits for a subset of uterine cancer patients with high-grade tumors. The gene discussed is ACTG1; the disease is uterine cancer.